Testing of Coding Algorithms for Inflammatory Bowel Disease Identification, as Indication for Use of Biological Drugs, Using a Claims Database from Southern Italy

References

• Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424–1429.
   PubMed Web of Science ®Google Scholar
• Romano C, Famiani A, Gallizzi R, Comito D, Ferrau’ V, Rossi P. Indeterminate colitis: a distinctive clinical pattern of inflammatory bowel disease in children. Pediatrics. 2008;122(6):e1278–81. doi:10.1542/peds.2008-2306
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K, GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. doi:10.1016/S2468-1253(19)30333-4
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54. doi:10.1053/j.gastro.2011.10.001
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel disease. Gastroenterology. 2011;140:1785–1794. doi:10.1053/j.gastro.2011.01.055
   PubMed Web of Science ®Google Scholar
• Burisch J, Pedersen N. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63:588–597. doi:10.1136/gutjnl-2013-304636
   PubMed Web of Science ®Google Scholar
• Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006. Inflamm Bowel Dis. 2011;17:2558–2565. doi:10.1002/ibd.21607
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Galeone C, Pelucchi C, Barbera G, Citterio C, La Vecchia C, Franchi A. Crohn’s disease in Italy: a critical review of the literature using different data sources. Dig Liver Dis. 2017;49:459–466. doi:10.1016/j.dld.2016.12.033
   PubMedGoogle Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: medical Treatment. J Crohns Colitis. 2020;14(1):4–22. doi:10.1093/ecco-jcc/jjz180
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD, Clinical Guideline ACG. Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. doi:10.14309/ajg.0000000000000152
   PubMed Web of Science ®Google Scholar
• Trifirò G, Gini R, Barone-Adesi F, et al. The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: where Does Italy Stand? Drug Saf. 2019;42(3):347–363. doi:10.1007/s40264-018-0732-5
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Giorgianni F, Bolcato J, et al. How much are biosimilars used in clinical practice? A retrospective Italian population-based study of erythropoiesis-stimulating agents in the years 2009–2013. BioDrugs. 2015;29(4):275–284. doi:10.1007/s40259-015-0132-7
   PubMed Web of Science ®Google Scholar
• Marcianò I, Ingrasciotta Y, Giorgianni F, et al. How did the introduction of biosimilar filgrastim influence the prescribing pattern of granulocyte colony stimulating factors? Results from a multicentre, population-based study, from five Italian centres in the years 2009–2014. BioDrugs. 2016;30(4):295–306. doi:10.1007/s40259-016-0175-4
   PubMed Web of Science ®Google Scholar
• Trifirò G, Isgrò V, Ingrasciotta Y, et al. VALORE Project Collaborators. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: the VALORE Project. BioDrugs. 2021;35(6):749–764. doi:10.1007/s40259-021-00498-3
   PubMed Web of Science ®Google Scholar
• Trifirò G, Isgrò V, Ingrasciotta Y, et al.; VALORE Project Collaborators. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: the VALORE Project. BioDrugs. 2021;35(6):749–764.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Guttmann A, Mack DR, et al. Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. J Clin Epidemiol. 2014;67(8):887–896. doi:10.1016/j.jclinepi.2014.02.019
   PubMed Web of Science ®Google Scholar
• Thirumurthi S, Chowdhury R, Richardson P, Abraham NS. Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans. Dig Dis Sci. 2010;55(9):2592–2598. doi:10.1007/s10620-009-1074-z
   PubMed Web of Science ®Google Scholar
• Lee H, Ford JA, Jin Y, et al. Validation of claims-based algorithms for psoriatic arthritis. Pharmacoepidemiol Drug Saf. 2020;29(4):404–408. doi:10.1002/pds.4950
   PubMed Web of Science ®Google Scholar
• Di Domenicantonio R, Cappai G, Arcà M, et al. Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. Dig Liver Dis. 2014;46(9):777–782. doi:10.1016/j.dld.2014.04.014
   PubMedGoogle Scholar
• Canova C, Simonato L, Barbiellini Amidei C, et al. A Systematic Review of Case-Identification Algorithms for 18 Conditions Based on Italian Healthcare Administrative Databases: a Study Protocol. Epidemiol Prev. 2019;43(4 Suppl 2):8–16. doi:10.19191/EP19.4.S2.P008.089
   PubMed Web of Science ®Google Scholar
• Ye Y, Manne S, Bennett D. Identifying Patients With Inflammatory Bowel Diseases in an Administrative Health Claims Database: do Algorithms Generate Similar Findings? Inquiry. 2019;56:46958019887816. doi:10.1177/0046958019887816
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Sultana J, Giorgianni F, et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One. 2014;9(2):e89072. doi:10.1371/journal.pone.0089072
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Giorgianni F, Bolcato J, et al. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013. BioDrugs. 2015;29(4):275–284.
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Lacava V, Marcianò I, et al. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrol. 2019;20(1):359. doi:10.1186/s12882-019-1554-0
   PubMed Web of Science ®Google Scholar
• Sultana J, Hurtado I, Bejarano-Quisoboni D, et al. Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. Eur J Clin Pharmacol. 2019;75(7):1005–1015. doi:10.1007/s00228-019-02654-9
   PubMed Web of Science ®Google Scholar
• Crisafulli S, Fontana A, L’Abbate L, et al. Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases. Sci Rep. 2022;12(1):15843. doi:10.1038/s41598-022-20295-4
   PubMed Web of Science ®Google Scholar
• Lee CK, Ha HJ, Oh SJ, et al. Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. J Gastroenterol Hepatol. 2020;35(5):760–768. doi:10.1111/jgh.14855
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35. doi:10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Bernstein CN. ”Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population based study. Am J Epidemiol. 1999;149:916–924. doi:10.1093/oxfordjournals.aje.a009735
   PubMed Web of Science ®Google Scholar
• Fonager K, Sørensen HT, Rasmussen SN, et al. Assessment of the diagnoses of Crohn’s disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol. 1996;31:pp. 154–159. doi:10.3109/00365529609031980
   Web of Science ®Google Scholar
• Lewis JD, Brensinger C, Bilker WB, Strom BL. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2002;11:pp. 211–218. doi:10.1002/pds.698
   Web of Science ®Google Scholar
• Rezaie A, Quan H, Fedorak RN, et al. Development and validation of an administrative case definition for inflammatory bowel diseases. Can J Gastroenterol. 2012;26(10):711–717. doi:10.1155/2012/278495
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Guttmann A, Mack DR. Validation of International Algorithms to Identify Adults with Inflammatory Bowel Disease in Health Administrative Data from Ontario, Canada. J Clin Epidemiol. 2014;vol. 67(8):887–896.
   Web of Science ®Google Scholar
• Coward S, Clement F, Benchimol EI, et al. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology. 2019;156(5):1345–1353.e4. doi:10.1053/j.gastro.2019.01.002
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Sangiorgi D, Perrone V, et al. Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study. Clinico Econ Outcomes Res. 2014;18(6):401–407. doi:10.2147/CEOR.S66338
   Google Scholar
• Chini F, Pezzotti P, Orzella L, Borgia P, Guasticchi G. Can we use the pharmacy data to estimate the prevalence of chronic conditions? A comparison of multiple data sources. BMC Public Health. 2011;11:688. doi:10.1186/1471-2458-11-688
   PubMed Web of Science ®Google Scholar
• Kim JW, Lee CK, Rhee SY, Oh CH, Shim JJ, Kim HJ. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: a nationwide population-based study. J Gastroenterol Hepatol. 2018;33(4):847–854. doi:10.1111/jgh.14027
   PubMed Web of Science ®Google Scholar
• Ladha KS, Eikermann M. Codifying healthcare--big data and the issue of misclassification. BMC Anesthesiol. 2015;15:179. doi:10.1186/s12871-015-0165-y
   PubMed Web of Science ®Google Scholar
• Gunaseelan V, Kenney B, Lee JS, Hu HM. Databases for surgical health services research: clinformatics Data Mart. Surgery. 2019;165(4):669–671. doi:10.1016/j.surg.2018.02.002
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency. Methotrexate SPC. Available from: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=033647. Accessed October 28, 2022.
   Google Scholar
• Italian Medicines Agency. Budesonide SPC. Available from: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=034734#. Accessed October 28, 2022.
   Google Scholar
• Italian Medicines Agency. Golimumab SPC. Available from: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=039541. Accessed October 28, 2022.
   Google Scholar
• Italian Medicines Agency. Balsalazide SPC. Available from: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=033858. Accessed October 28, 2022.
   Google Scholar
• Italian Medicines Agency. Mesalazine SPC. Available from: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/cerca-per-principio-attivo?princ_att=MESALAZINA%20(5-ASA). Accessed October 28, 2022.
   Google Scholar